Interleukin-17A Antagonist

Interleukin-17A Antagonists

Psoriasis

<section class="Section" data-sectioncode="34089-3"><a name="s53"></a><a name="section-8"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) with neutralizing activity against IL-17A. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule.</p><p>TALTZ injection is a sterile, preservative free, clear and colorless to slightly yellow solution, for subcutaneous use available as 80 mg of ixekizumab in a 1 mL single-dose prefilled autoinjector or a single-dose prefilled syringe. The prefilled autoinjector and prefilled syringe each contain a 1 mL glass syringe with a fixed 27 gauge ½ inch needle. The TALTZ 80 mg prefilled autoinjector and prefilled syringe are manufactured to deliver 80 mg of ixekizumab.</p><p>Each mL is composed of ixekizumab (80 mg); Polysorbate 80, USP (0.3 mg); Sucrose, USP (80 mg); and Water for Injection, USP. Sodium Hydroxide, USP-NF, may have been added to adjust pH. The TALTZ solution has a pH of 5.2 –  6.2.</p></section>

Taltz | The Zangmeister Cancer Center

Does The Zangmeister Cancer Center work closely with Taltz and Eli Lilly and Company?

Does The Zangmeister Cancer Center offer services for Taltz patients?

What conditions does The Zangmeister Cancer Center support?